COMPOSITIONS AND METHODS FOR DETECTION OF CHROMOSOMAL ABERRATIONS WITH NOVEL HYBRIDIZATION BUFFERS

(19)

(11)

EP 3 138 925 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	17.06.2020 Bulletin 2020/25

(45)	Mention of the grant of the patent:
	13.05.2020 Bulletin 2020/20

(21)	Application number: 16180119.6

(22)	Date of filing: 27.05.2009

(51)

International Patent Classification (IPC):

C12Q 1/6832^(2018.01)

C12Q 1/6841^(2018.01)

(54)

COMPOSITIONS AND METHODS FOR DETECTION OF CHROMOSOMAL ABERRATIONS WITH NOVEL HYBRIDIZATION BUFFERS

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR ERKENNUNG VON CHROMOSOMALEN ABWEICHUNGEN MIT NEUEN HYBRIDISIERUNGSPUFFERN

COMPOSITIONS ET PROCÉDÉS POUR LA DÉTECTION D'ABERRATIONS CHROMOSOMIQUES AVEC DE NOUVEAUX TAMPONS D'HYBRIDATION

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30)

Priority:

27.05.2008 US 56089 P
27.05.2008 DK 200800727
26.02.2009 US 155683 P
27.02.2009 DK 200900278

(43)	Date of publication of application:
	08.03.2017 Bulletin 2017/10

(60)	Divisional application:
	20167307.6

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	13164094.8 / 2636756
	09757890.0 / 2285982

(73)	Proprietor: Agilent Technologies, Inc.
	Santa Clara, CA 95051 (US)

(72)	Inventors:
	MATTHIESEN, Steen Hauge 3400 Hillerød (DK) PETERSEN, Kenneth H. 2765 Smørum (DK) POULSEN, Tim Svenstrup 2970 Hørsholm (DK)

(74)	Representative: Grünecker Patent- und Rechtsanwälte PartG mbB
	Leopoldstraße 4 80802 München 80802 München (DE)

(56)

References cited: :

WO-A1-00/69899
US-A- 4 886 741

WO-A1-92/07956
US-A- 5 521 061

OLSEN K.E. ET AL.,: "amplification of HER2 and TOP2A and deletion of TOP2a genes in breast cancer investigated by new FISH probes", ACTA ONCOLOGICA, vol. 43, no. 1, 2004, pages 34-42, XP009127838,
Anonymous: "TOP2A FISH pharmDx kit Code K5333", DAKO PRODUCT INFORMATION , 24 May 2007 (2007-05-24), pages 1-33, XP002562618, Retrieved from the Internet: URL:http://www.dakogmbh.de/prod_downloadpa ckageinsert.pdf?objectid=114968002 [retrieved on 2010-01-12]

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).